Pharvaris B.V. (PHVS) Stock Forecast & Price Target

Pharvaris NV is enhancing its financial outlook significantly, raising the global peak sales estimate for its lead candidate, deucrictibant, to $1.65 billion by 2037, up from a previous estimate of $1.4 billion. Positive clinical outcomes are highlighted by the achievement of "well-controlled HAE" status in 100% of participants according to the Angioedema Control Test and reported improvements in health-related quality of life among all participants receiving the therapeutic dose. Given the estimated prevalence of HAE combined with an absence of approved treatments, deucrictibant is poised to capture substantial market share if successful in clinical trials, underscoring its potential as a best-in-class oral therapy in this niche patient population.

Pharvaris NV faces significant challenges in the competitive hereditary angioedema (HAE) market, where established therapies dominate, raising concerns about the potential market penetration of its novel treatments. The company's reliance on bradykinin B2 receptor antagonism in chronic prophylaxis is viewed as inadequately de-risked, which may hinder investor confidence in the long-term success of its pipeline. Additionally, the development of multiple subcutaneous therapies anticipated to receive approval within the next three years poses a further risk by potentially eroding Pharvaris's market share and limiting the uptake of its product, deucrictibant.